Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Article

Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant 1 Supported by a grant from the National Health and Medical Research Council of Australia (NHMRC). M. F. is recipient of an Australian Postgraduate Award. L. K. A. is a NHMRC Principal Research Fellow. Imatinib was provided by Novartis. 1

Michelle J. Frost, Petranel T. Ferrao, Timothy P. Hughes and Leonie K. Ashman
Michelle J. Frost
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petranel T. Ferrao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy P. Hughes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonie K. Ashman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published October 2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Surface expression levels of c-Kit in FDC-P1 (A), FDC(WTKit) (B), FDC(V560GKit) (C), and FDC(D816VKit) (D), detected by immunofluorescence/flow cytometry with MAb IDC3 (antihuman c-Kit), are compared with an isotype-matched control MAb (dashed line).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Differential sensitivity of V560GKit and D816VKit to Imatinib. FDC expressing GNNK−/S+ WTKit, GNNK−/S+ V560GKit, and GNNK−/S+ D816VKit were cultured for 48 h in the presence of Imatinib (at the concentrations indicated on the X axis). Growth was assessed using a colorimetric assay for viable cell number. In A, cells were cultured in mGM-CSF. In B, WTKit were cultured in 100 ng/ml hu-SCF. V560GKit (C) and D816VKit (D) lines were cultured without added factors. Abs, absorbance.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Imatinib induces apoptosis in FDC(WTKit) and FDC(V560GKit). FDC-P1, FDC(WTKit), FDC(V560GKit), and FDC(D816VKit) were cultured in the presence of Imatinib and factors as indicated for 24 h. Apoptotic cells were detected by staining with Annexin-V and analysis by flow cytometry.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    GNNK+/− and S+/− isoforms do not differ in sensitivity to Imatinib. FDC expressing GNNK+/S+ WTKit, GNNK+/S- WTKit, GNNK−/S+ WTKit, GNNK+/S+ D816VKit, and GNNK−/S+ D816VKit were cultured in the presence of Imatinib for 48 h. Growth was assessed using a colorimetric assay for viable cell number. In A, cells were cultured in mGM-CSF. In B, WTKit lines were cultured in 100 ng/ml hu-SCF, and D816VKit lines were cultured in the absence of added factors. Abs, absorbance.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Effect of Imatinib on phosphorylation of c-Kit. In A, FDC(WTKit), FDC(V560GKit), and FDC(D816VKit) were incubated in the absence of serum for 2 h with the indicated concentrations of Imatinib. FDC(WTKit) were then pulsed with 100 ng/ml SCF for 2 min. Cells were lysed and immunoprecipitation and Western blot analysis was performed as described in “Materials and Methods.” kDa, molecular weight in thousands. In B and C, Kit and phosphotyrosine bands were quantitated using ImageQuant software. All of the values are relative to WTKit stimulated with SCF (Lane 2), which was assigned an arbitrary value of 1. The extent of phosphorylation is represented as phosphorylated Kit/cell number (B) and the ratio of phosphorylated Kit:total Kit for the same number of cells (C).

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Effect of Imatinib on the activation of downstream signaling pathways. FDC-P1, FDC(WTKit), FDC(V560GKit), and FDC(D816VKit) were incubated in the absence of serum for 2 h with the indicated concentrations of Imatinib. Cells were pulsed with hu-SCF for 2 min or mGM-CSF (GM) for 15 min. Cells were lysed and Western blot analysis was performed as described in “Materials and Methods.” MW, molecular weight in thousands.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 1 (12)
October 2002
Volume 1, Issue 12
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant 1 Supported by a grant from the National Health and Medical Research Council of Australia (NHMRC). M…
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
Citation Tools
Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant 1 Supported by a grant from the National Health and Medical Research Council of Australia (NHMRC). M. F. is recipient of an Australian Postgraduate Award. L. K. A. is a NHMRC Principal Research Fellow. Imatinib was provided by Novartis. 1
Michelle J. Frost, Petranel T. Ferrao, Timothy P. Hughes and Leonie K. Ashman
Mol Cancer Ther October 1 2002 (1) (12) 1115-1124;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant 1 Supported by a grant from the National Health and Medical Research Council of Australia (NHMRC). M. F. is recipient of an Australian Postgraduate Award. L. K. A. is a NHMRC Principal Research Fellow. Imatinib was provided by Novartis. 1
Michelle J. Frost, Petranel T. Ferrao, Timothy P. Hughes and Leonie K. Ashman
Mol Cancer Ther October 1 2002 (1) (12) 1115-1124;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement